Skip to main content
Premium Trial:

Request an Annual Quote

Horizon Discovery to Develop Drug Sensitivity Panel for DxS

NEW YORK (GenomeWeb News) – Horizon Discovery said today that it will develop a panel of human isogenic cell models of drug sensitivity and resistance mechanisms in cancer patients for DxS to use in its pharmacogenetic program.

DxS will use the panel to continue to develop its TheraScreen clinical diagnostic kits.

Horizon will use its gene engineering technology, called GENESIS, to generate a range of mutant and normal cell lines that will serve as a source of DNA that will be used to assess the performance of the TheraScreen K-RAS Mutation Kits, which are used to determine which patients will respond to anti-EGFR targeted colorectal cancer treatments, including Erbitux and Vectibix.

"Our initial focus will be on evaluating new diagnostic kits from DxS using isogenic human mutant vs. normal DNA-controls, which we feel represent a 'gold-standard' means of bench-marking companion diagnostics where mutations often need to be detected in humans within a background of excess isogenic normal DNA," Horizon's CEO, Chris Torrance, said in a statement.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.